The BCR, the key protein for every B-lymphocyte, not surprisingly modulates CLL cells biology as well; several signaling molecules downstream of the BCR such as kinases and TFs are involved, and they have been recently targeted for therapeutic purposes (58, 59). The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.